抵克力得预防重组人促红细胞生成素诱发顽固性高血压和血 …

目的：研究抵克力得预防重组人促红细胞生成素（ｒＨｕＥＰＯ）治疗维持性血液透析患者肾性贫血所诱发的顽固性高血压和血栓症的机制和疗效。方法：将１７例患者随机分为两种，治疗组１０例，在ｒＨｕＥＰＯ治疗同时使用抵克力得，对照组７例，只使用ｒＨｕＥＰＯ。两组均治疗１２周，然后比较治疗前后两组血液学及血流动力学指标的改变及临床疗效。结果：对照组血红蛋白（Ｈｂ）、红细胞压积（ＨＣＴ）、平均血压（ＭＢＰ）和血小板

Clinical study of ticlopidine for prevention of hypertension and thrombosis induced by recombinant human erythropoietin (rHuEPO)

Purpose: To study the mechanism and curative effect of Ticlopidine for prevention of hypertension and thrombosis induced by rHuEPO. Methods: 17 cases of uremic patients were divided into two groups at random. In therapeutic group, 10 cases received rHuEPO and Ticlopidine treatment simultaneously. In control group, 7 cases only received rHuEPO treatment. The indexes of hemology and hemodynamics were compared between before and after treatment. Results: In control group, the levels of Hb, HCT, MBP and BPC rasied obviously, the levels of BT and CT shortened, and hypertension and thrombosis occurred in 3 cases respectively. But in therapeutic group, the levels of CT and MBP unchanged, BT value prolonged, no hypertension and thrombosis occurred. Conclusions: The changes of platelet aggressive ability induced by rHuEPO may be involved in the pathogenesis of hypertension and thrombosis and Ticlopidine may effectively inhibit this process to prevent hypertension and thrombosis induced by rHuEPO.